Logo image of TRML

TOURMALINE BIO INC (TRML) Stock Fundamental Analysis

NASDAQ:TRML - Nasdaq - US89157D1054 - Common Stock - Currency: USD

16.01  +1.49 (+10.26%)

After market: 15.3684 -0.64 (-4.01%)

Fundamental Rating

3

TRML gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While TRML has a great health rating, there are worries on its profitability. TRML is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRML has reported negative net income.
In the past year TRML has reported a negative cash flow from operations.
TRML had negative earnings in each of the past 5 years.
TRML had a negative operating cash flow in each of the past 5 years.
TRML Yearly Net Income VS EBIT VS OCF VS FCFTRML Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of TRML (-23.69%) is better than 74.65% of its industry peers.
TRML's Return On Equity of -24.40% is amongst the best of the industry. TRML outperforms 83.10% of its industry peers.
Industry RankSector Rank
ROA -23.69%
ROE -24.4%
ROIC N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
TRML Yearly ROA, ROE, ROICTRML Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRML so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRML Yearly Profit, Operating, Gross MarginsTRML Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

TRML has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRML has more shares outstanding
There is no outstanding debt for TRML. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRML Yearly Shares OutstandingTRML Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
TRML Yearly Total Debt VS Total AssetsTRML Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 27.01 indicates that TRML is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.01, TRML belongs to the top of the industry, outperforming 96.48% of the companies in the same industry.
TRML has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.01
ROIC/WACCN/A
WACCN/A
TRML Yearly LT Debt VS Equity VS FCFTRML Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

TRML has a Current Ratio of 30.18. This indicates that TRML is financially healthy and has no problem in meeting its short term obligations.
TRML has a Current ratio of 30.18. This is amongst the best in the industry. TRML outperforms 98.42% of its industry peers.
A Quick Ratio of 30.18 indicates that TRML has no problem at all paying its short term obligations.
The Quick ratio of TRML (30.18) is better than 98.42% of its industry peers.
Industry RankSector Rank
Current Ratio 30.18
Quick Ratio 30.18
TRML Yearly Current Assets VS Current LiabilitesTRML Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

TRML shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.72%, which is quite impressive.
EPS 1Y (TTM)71.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TRML is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.41% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-23.63%
EPS Next 2Y-21.35%
EPS Next 3Y-21.63%
EPS Next 5Y1.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRML Yearly Revenue VS EstimatesTRML Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
TRML Yearly EPS VS EstimatesTRML Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TRML reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TRML is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRML Price Earnings VS Forward Price EarningsTRML Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRML Per share dataTRML EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as TRML's earnings are expected to decrease with -21.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.35%
EPS Next 3Y-21.63%

More info and screens

0

5. Dividend

5.1 Amount

TRML does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TOURMALINE BIO INC

NASDAQ:TRML (4/17/2025, 8:00:00 PM)

After market: 15.3684 -0.64 (-4.01%)

16.01

+1.49 (+10.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners86.04%
Inst Owner Change0.04%
Ins Owners10.92%
Ins Owner Change0%
Market Cap411.30M
Analysts86.25
Price Target53.91 (236.73%)
Short Float %17.26%
Short Ratio11.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.64%
Min EPS beat(2)2.86%
Max EPS beat(2)6.42%
EPS beat(4)4
Avg EPS beat(4)8.79%
Min EPS beat(4)2.86%
Max EPS beat(4)19.32%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.36%
PT rev (3m)-7.73%
EPS NQ rev (1m)-4.05%
EPS NQ rev (3m)3.2%
EPS NY rev (1m)2.56%
EPS NY rev (3m)2.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-2.87
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-3.01
FCFYN/A
OCF(TTM)-3.01
OCFYN/A
SpS0
BVpS11.68
TBVpS11.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.69%
ROE -24.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.29%
ROA(5y)-23.15%
ROE(3y)-28.66%
ROE(5y)-24.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.08%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 30.18
Quick Ratio 30.18
Altman-Z 27.01
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)137.69%
Cap/Depr(5y)218.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
EPS Next Y-23.63%
EPS Next 2Y-21.35%
EPS Next 3Y-21.63%
EPS Next 5Y1.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-113.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-174.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-175.14%
OCF growth 3YN/A
OCF growth 5YN/A